Polarean Imaging (GB:POLX) has released an update.
Polarean Imaging PLC, a leader in advanced MRI technology for lung function, has disclosed that Bill Blair, an Independent Non-Executive Director, sold a significant number of shares. The company, known for its FDA-approved hyperpolarised Xenon MRI contrast agent, XENOVIEW™, caters to over 500 million patients globally with chronic respiratory diseases. This move comes as Polarean continues to innovate in the medical imaging field, aiming to transform pulmonary medicine and improve lung health.
For further insights into GB:POLX stock, check out TipRanks’ Stock Analysis page.
